BioSpace News Archive

Inhibikase Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and highlighted recent developments.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced its financial and operating results for the first quarter of 2022.

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

ASC Therapeutics will provide a comprehensive review of IND-enabling studies of ASC618, a second-generation gene therapy for hemophilia A, at the 25th Annual Meeting of The American Society of Gene and Cell Therapy held May 16-19, 2022 in Washington, D.C. These studies were included in a filing to the U.S. Food and Drug Administration leading to IND clearance of ASC618.

CANbridge Pharmaceuticals Inc. announced the presentation of the initial data from its gene therapy research agreement with the Horae Gene Therapy Center, at the UMass Chan Medical School, at the ASGCT 25th Annual Meeting, in Washington DC.

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced encouraging data from phase 1 and preclinical DDI studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.

Asklepios BioPharmaceutical, Inc. announced that the Company will present 11 abstracts at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting being held May 16 – 19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.

A study led by researchers at Alife Health, a fertility technology company building artificial intelligence (AI) tools designed to improve in-vitro fertilization (IVF) outcomes, found that an interpretable machine learning model can help doctors optimize ovulation trigger injection timing to improve patient outcomes for a significant number of patients.

The growing demand for integrating AI-enabled algorithms in diagnostics to provide precise and accurate diagnosis at the earliest, which enhances clinical and operational outcomes, is driving the growth of this market.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.